Abstract: A method of forming an optical device in a body (32), comprises performing a plurality of laser scans (34,36) to form the optical device, each scan comprising relative movement of a laser beam and the body thereby to scan the laser beam along a respective path (34a, 34b 34f; 36a, 36b 36f) through the body to alter the refractive index of material of that path, wherein the paths are arranged to provide in combination a route for propagation of light through the optical device in operation that is larger in a direction substantially perpendicular to the route for propagation of light than any one of the paths individually.

Abstract: The present invention relates to structure including an interfacial seal between a glass-ceramic component and a metal component, as well as methods for forming such structures. In particular embodiments, the interfacial seal includes a metal oxide. Such interfacial seals can be beneficial for, e.g., hermetic seals between a glass-ceramic component and a metal component.

Abstract: The present invention pertains to a method for manufacturing cement, wherein the gypsum is first calcined separately before being inter-grinded with the clinker so as to minimize the release of water of crystallization of during the inter-grinding stage. The method produces cement of high strength at all ages, better rheology, enables higher use of fly ash, and reduces CO2 emission during manufacturing.

Abstract: A repaired reinforced concrete structure is provided which includes one or more reinforcing steel bars of cross-sectional area Ax, the one or more reinforcing steel bars having one or more corroded sections of cross-sectional area Ay, wherein Ay is greater than or equal to approximately 0.6 Ax. A reinforced ordinary Portland cement-based repair mortar is positioned directly on the one or more corroded sections of the one or more reinforcing steel bars without the addition of a lapped reinforcing steel bar. The reinforced repair mortar includes at least approximately 1 percent by volume of reinforcing steel fibers such that the reinforced repair mortar restores a strength of a repaired region to greater than approximately 100% of an original strength of the concrete structure in an uncorroded state. The repaired reinforced concrete structure is highly durable, as the repair mortar exhibits an air permeability resistance of greater than 1000 seconds.

Abstract: A ceramic heat shield for a gas turbine. The ceramic heat shield has a ceramic body containing aluminium oxide and has a surface layer of the ceramic body which contains yttrium aluminium garnet as reaction coating material. A gas turbine includes such a ceramic heat shield and a method produces such a ceramic heat shield.

Abstract: Luminescent concrete compositions containing cement, fine aggregates such as sand, and a phosphor such as strontium aluminate. Glow-in-the-dark concrete products made therefrom and methods of producing such concrete products are also specified. The glow-in-the-dark concrete products demonstrate good mechanical strength (e.g. compressive strength) and skid resistance. The addition of phosphorescent strontium aluminate provides luminance that persists for up to 10 hours to the concrete products.

Abstract: Systems and methods for producing potassium sulfate. Such a method involves providing an industrial waste material that includes at least one metal sulfate or a metal product that has been reacted with sulfuric acid to produce metal sulfates, and then reacting the metal sulfate with potassium carbonate to produce a byproduct that contains potassium sulfate.

Abstract: The disclosure relates to a composting device including a housing defining an interior with an access opening providing access to the interior, a composter bin located within the interior and in communication with the access opening, and a door mounted to the housing and electrically powered to automatically slide along a sliding path between opened and closed position.

Abstract: Reaction products and methods for making and using such reaction products are provided. For example, a reaction product comprising an adduct formed from two or more of a first nucleophile (e.g., including, but not limited to, a urease inhibitor), a second nucleophile, and an electrophile is described, which can be provided in various forms. Such a reaction product can be in the form of a solid or solution. Such a reaction product can also be combined with one or more additional components, including but not limited to, free urease inhibitor and/or a nitrogen-based fertilizer composition.

Abstract: The present invention relates to an emulsion composition for an explosive and to a method of preparing the same, wherein the emulsion composition includes, based on the total weight thereof, 85 to 95 wt % of an oxidizing agent aqueous solution, 0.3 to 5 wt % of an emulsifier, and 3 to 10 wt % of oil, the emulsifier including a PIBSA (polyisobutylene succinic anhydride) amine salt having an acid value of 30 or less and an amine value of 45 to 65, under a precondition that the oxidizing agent aqueous solution includes at least one of industrial ammonium nitrate, agricultural ammonium nitrate and low-specific-gravity ammonium nitrate for an ammonium nitrate fuel oil explosive, which is used without additional filtration or removal of impurities.

Abstract: Nanowires useful as heterogeneous catalysts are provided. The nanowire catalysts are prepared by polymer templated methods and are useful in a variety of catalytic reactions, for example, the oxidative coupling of methane to ethane and/or ethylene. Related methods for use and manufacture of the same are also disclosed.

Abstract: The present disclosure relates to processes that catalytically convert a hydrocarbon feed stream predominantly comprising both isopentane and n-pentane to yield upgraded hydrocarbon products that are suitable for use either as a blend component of liquid transportation fuels or as an intermediate in the production of other value-added chemicals. The hydrocarbon feed stream is isomerized in a first reaction zone to convert at least a portion of the n-pentane to isopentane, followed by catalytic-activation of the isomerization effluent in a second reaction zone with an activation catalyst to produce an activation effluent. The process increases the conversion of the hydrocarbon feed stream to olefins and aromatics, while minimizing the production of C1-C4 light paraffins. Certain embodiments provide for further upgrading of at least a portion of the activation effluent by either oligomerization or alkylation.

Abstract: An alkylation process including an upfront isomerization zone is described. 100% n-butane or field butanes can be converted into a blend of approximately 60 wt % isobutane and 40 wt % n-butane in the isomerization zone. This blend can be used as the feed to all types of alkylation zones. It stabilizes the feed composition so that the dehydrogenation zone and alkylation zone always operate with the same feed.

Abstract: Methods for the manufacture of 1,1,1,2,3-pentachloropropane from 1,1,1,3-tetrachloropropane and chlorine are disclosed. Improved methods are provided for the manufacture of 1,1,2,3-tetrachloropropene from 1,1,1,2,3-pentachloropropane. Methods are also disclosed for the manufacture of 1,1,2,3-tetrachloropropene from 1,1,1,3-tetrachloropropane and chlorine and for the manufacture of 1,1,2,3-tetrachloropropene from carbon tetrachloride, ethylene, and chlorine.

Abstract: Methods for producing ethylene glycol from a carbohydrate feed which may include preparing a feed solution including the carbohydrate feed, a soluble retro-Aldol catalyst, and an acid. The feed solution may be contacted, in a reactor under hydrogenation conditions, with a heterogeneous hydrogenation catalyst. A product stream including ethylene glycol may be obtained from the reactor.

Abstract: The present disclosure provides a composition comprising a surfactant compound containing aromatic groups in the hydrophobe. Also disclosed are personal care formulations and performance chemical formulations, such as agrochemical formulations, that comprise such surfactant compounds.

Abstract: A method for manufacturing 1,4-bis(4-phenoxybenzoyl)benzene, including: reacting terephthaloyl chloride with diphenyl ether in a reaction solvent and in the presence of a Lewis acid, so as to obtain a product mixture comprising a 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex; putting the product mixture in contact with an aqueous solution, so as to obtain an aqueous phase containing the Lewis acid and an organic phase containing 1,4-bis(4-phenoxybenzoyl)benzene.

Abstract: The invention relates to a process for hydroformylating short-chain olefins, especially C2 to C5 olefins, in which the catalyst system is in heterogenized form on a support of a porous ceramic material, and to plants for performing this process.

Abstract: The invention relates to a process for hydroformylating short-chain olefins, especially C2 to C5 olefins, in which the catalyst system is in heterogenized form on a support of a porous ceramic material, and to plants for performing this process.

Abstract: Methods for preparing isotopically modified 1,4-diene systems from non-isotopically modified 1,4-dienes involve selective oxidation of one or more bis-allylic position(s), or the preparation of isotopically modified 1,4-diene systems via trapping pi-allylic complexes with a source of deuterium or tritium. Such methods are useful for preparing isotopically modified polyunsaturated lipid including polyunsaturated fatty acids and polyunsaturated fatty acid derivatives.

Abstract: Provided is a method for purifying 1,5-pentanediamine comprising: providing 1,5-pentanediamine to be purified and treating the 1,5-pentanediamine to be purified by a reduction reaction to obtain purified 1,5-pentanediamine. Meanwhile, further provided is 1,5-pentanediamine prepared by the method. The purification method has a concise process and a simple operation, and is suitable for industrial production, and can significantly improve the quality of 1,5-pentanediamine.

Abstract: A family of amine mining collectors that uses alkoxylates allows for the easy adjustment of solubility and molecular weight useful because anionic and cationic mineral collectors require such varying degrees of solubility and molecular weight. The family of the present invention allows for the optimization of both parameters and an increase in collector efficiency.

Abstract: Acrylamide photoinitiators are provided, in which a photoinitiator moiety and an acrylamide are incorporated into the photoinitiator structure.

Abstract: The instant invention concerns a gas hydrate inhibitor comprising an N alkyl N? (N?,N?-dialkylammoniumalkyl)dicarboxylic acid diamide salt represented by the formula (I) wherein R is an alkyl or alkenyl group having from 8 to 22 carbon atoms, R1 is hydrogen, a C1- to C22 alkyl group or a C3- to C22 alkenyl group, R2 and R3 are each independently an alkyl group containing 1 to 10 carbon atoms or together form an optionally substituted ring having 5 to 10 ring atoms, wherein the ring may carry up to 3 substituents, R4 is hydrogen, A is an optionally substituted hydrocarbyl group containing from 1 to 18 carbon atoms, B is an alkylene group having from 2 to 6 carbon atoms, Y is NR5, R5 is hydrogen, a C1- to C22 alkyl group or a C3- to C22 alkenyl group, and M? is an anion, a process for producing a compound according to formula (I), the use of an N alkyl N?-(N?,N?-dialkylammoniumalkyl)dicarboxylic acid diamide salt of the formula (I) as an anti-agglomerant for gas hydrates, and a method for inhibiti

Abstract: A process for the production of formaldehyde-stabilised urea is described comprising the steps of: (a) generating a synthesis gas; (b) subjecting the synthesis gas to one or more stages of water-gas shift in one or more water-gas shift reactors to form a shifted gas; (c) cooling the shifted gas to below the dew point and recovering condensate to form a dried shifted gas; (d) recovering carbon dioxide from the dried shifted gas in a carbon dioxide removal unit to form a carbon dioxide-depleted synthesis gas; (e) synthesising methanol from the carbon dioxide-depleted synthesis gas in a methanol synthesis unit and recovering the methanol and a methanol synthesis off-gas; (f) subjecting at least a portion of the recovered methanol to oxidation with air to form formaldehyde in a stabiliser production unit; (g) subjecting the methanol synthesis off-gas to methanation in a methanation reactor containing a methanation catalyst to form an ammonia synthesis gas; (h) synthesising ammonia from the ammonia synthesis gas i

Abstract: Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.

Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

Abstract: The present invention discloses processes for producing methyl ethyl sulfide by contacting dimethyl sulfide and diethyl sulfide in the presence of a suitable catalyst. Methyl ethyl sulfide can be used as an odorant in natural gas. Integrated mercaptan and sulfide manufacturing systems and integrated methods for making mercaptans and sulfides also are disclosed.

Abstract: Disclosed are sulfide-based compounds which are a product of a Michael addition reaction between a sulfur-containing donor group and an unsaturated hydrocarbon moiety. The sulfide-based compounds may be used in compositions and methods for inhibiting corrosion.

Abstract: Disclosed herein is a compound of Formula I, wherein R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention, relates to solid state forms of N-[2-[(1 S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide represented by the following structural formula-1 and process for their preparation. The present invention also relates to an improved process for the preparation of N-[2-[(1 S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide compound of formula-1 and intermediates thereof.

Abstract: The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

Abstract: A method for preparing chromium(III) pyridine-2-carboxylate using 2-OP rectification residues, including: subjecting the 2-OP rectification residues to in-situ catalytic pyrolysis and vacuum distillation, room-temperature crystallization and separation, recrystallization and dehydration, alkali-catalyzed hydrolysis, acidification and complexation, and separation, washing and drying to prepare a chromium(III) pyridine-2-carboxylate product, of which a yield is greater than 50% of the weight of the 2-OP rectification residues. The acidification and complexation includes: cooling the aqueous solution containing sodium pyridine-2-carboxylate obtained from the alkali-catalyzed hydrolysis to a temperature below 50° C.; adjusting the aqueous solution to pH 3.0-8.5 with 5-50 wt % dilute H2SO4 or 3-30 wt % dilute HCl followed by batchwise addition of CrCl3, Cr(NO3)3 or Cr2(SO4)3 for complexation at 20-70° C.

Abstract: The present disclosure provides certain compositions and methods useful in the treatment and/or prevention of a neurodevelopmental disorder, such as seizure disorders, autism or an autism spectrum disorder (ASD). More specifically, this includes compositions that contain at least one fenamate active agent, which are analogs to mefenamic acid and/or derivatives thereof, where such compositions exhibit increased solubility over MFA. The increased solubility provides for the potential for increased therapeutic action, when used in therapeutic treatment of Autism, Autism Spectrum Disorders (ASDs), seizures and neurodegenerative disorders over other known MFA analogs. In addition, these MFA analogs are effective in preventing an increase in permeability of the blood-brain barrier (BBB) without adversely altering brain metabolite levels, but at effective dosages restoring seizure effects and brain metabolites back to their normal levels.

Abstract: The invention provides (1) processes for making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; (2) compositions useful in making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives.

Abstract: A method for producing substantially pure levorphanol and related compounds, when compared to the conventional process, is provided. In particular, a method for producing substantially pure levorphanol tartrate dihydrate is described. Also described are compositions comprising levorphanol and related compounds, particularly compositions comprising levorphanol tartrate dihydrate, levomethorphan, and norlevorphanol in which the levomethorphan and norlevorphanol are present in the composition in reduced levels.

Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein.

Abstract: Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:

Abstract: Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, agricultural compositions containing them and their use as herbicides (Formula 1), wherein R1, R2, L, G and W are as defined in the disclosure, and A is selected from (Formula A-1, A-2, A-3, A-4, A-5, A-6, A-7, A-8, A-9 and A-19) and X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, Y and Y1 are as defined in the disclosure.

Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

Abstract: In a process for the epoxidation of propene, comprising continuously reacting a propene feed with hydrogen peroxide in the presence of an epoxidation catalyst in a reaction step, using propene in excess to hydrogen peroxide, to provide a liquid reaction mixture comprising non-reacted propene, extra safety measures caused by the presence of oxygen during work-up of the liquid reaction mixture of the epoxidation reaction can be avoided by stripping liquid reaction mixture from step a) with an inert gas to provide an oxygen depleted stripped liquid reaction mixture and a strip gas stream, selecting the amount of inert gas to provide an oxygen concentration in the strip gas stream in the range of from 0.1 to 10% by weight, separating non-reacted propene from the strip gas stream and recycling it to the reaction step, and separating propene oxide from the stripped liquid reaction mixture.

Abstract: Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Abstract: Provided is a compound represented by formula (I): or an N-oxide compound thereof, wherein the variable groups are as defined in the specification. Also provided is an arthropod pest control agent containing a compound represented by formula (I) and an inert carrier. The compound represented by formula (I) and arthropod pest control agent exhibit an excellent controlling effect against arthropod pests.

Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or disorders.

Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.

Abstract: Disclosed is a process for preparing Compound 8: (8) comprising the step of reacting Compound of 7: (7) wherein R is C1-8 alkyl or benzyl in the presence of a base. Also disclosed are intermediates and processes for preparing the intermediates.